NEW YORK (GenomeWeb) – Pharmacogenomic testing firm AltheaDx announced today that it has closed a $27 million Series D financing round.

AltheaDx sells a portfolio of tests — marketed under the IDgenetix brand name — that analyze genes involved in the metabolism and pharmacological activity of drugs, to provide clinicians with information about the functionality of metabolic enzymes and biological drug targets for a specific patient.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.